Compared to daily oral pre-exposure prophylaxis (PrEP), lenacapavir reduces the number of new HIV infections by many more; causes slightly fewer serious unwanted effects; and results in little to no ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results